KPP
EW icon

Kings Path Partners’s Edwards Lifesciences EW Stock Holding History

Kings Path Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$724 Buy
+8
New +$670 ﹤0.01% 335

Other funds holding EW

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
FFM
Fisher Funds Management Auckland, New Zealand $3.52B AUM 17.59% 1-Year Est. Return

Kings Path Partners's EW Position: Q2 2026 in Review

Kings Path Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 8 shares worth $724. The stake represents ﹤0.01% of the portfolio and ranks #335 among its holdings.

265 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Kings Path Partners held 8 shares of Edwards Lifesciences worth $724 as of Q2 2026.
  • Edwards Lifesciences was a new Kings Path Partners position in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Kings Path Partners's portfolio in Q2 2026, its #335 holding.
  • 265 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Kings Path Partners's 13F filing for Q2 2026, filed 14 Jul 2026.